Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Rao · SciRah

Researcher profile · Semantic Scholar

N. Rao

Share profile

N. Rao — researcher profile on SciRah

h-index: 9
Works: 28
Citations: 542

Most-cited papers

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
K. Pratz, J. Cortes, G. Roboz, N. Rao +8 more
2009Blood186 citations Open access
Semantic Scholar
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study†
R. Bissonnette, C. Maari, S. Forman, N. Bhatia +14 more
2019British Journal of Dermatology114 citations Open access
Semantic Scholar
Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis.
A. Pavel, T. Song, Hyun Je Kim, E. Del Duca +12 more
2019Journal of Allergy and Clinical Immunology99 citations Open access
Semantic Scholar
A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML
J. Cortes, G. Roboz, H. Kantarjian, E. Feldman +5 more
200837 citations
Semantic Scholar
Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study.
Pablo A. Jiménez, H. Sofen, R. Bissonnette, Mark Lee +6 more
2023Journal of American Academy of Dermatology34 citations Open access
Semantic Scholar
ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
R. Smith, D. Zammit, N. Damle, H. Usansky +6 more
2021Molecular Cancer Therapeutics21 citations Open access
Semantic Scholar
559 ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients
E. Guttman-Yassky, A. Pavel, T. Song, H. Kim +3 more
201811 citations Open access
Semantic Scholar
A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.
J. Cortes, G. Roboz, H. Kantarjian, E. Feldman +6 more
200711 citations
Semantic Scholar
Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition
K. Pratz, A. Stine, J. Karp, D. Small +6 more
20089 citations
Semantic Scholar
ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.
D. Rasco, R. Sullivan, N. Lakhani, Sanjeeva P. Reddy +4 more
20173 citations
Semantic Scholar
ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies
N. Rao, Sanjeeva P. Reddy, Gupta Sandeep, N. Damle +9 more
20153 citations
Semantic Scholar
Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models
S. Thompson, M. Jaleel, Vijay Kumar Nyavanandi, M. Ramachandra +7 more
20153 citations
Semantic Scholar
Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.
Stefan K. Barta, D. Rasco, Andy I. Chen, Stephanie Elkins +6 more
20182 citations
Semantic Scholar
Abstract 4204: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models
Sanjeeva P. Reddy, N. Rao, D. Zammit, S. Thompson +2 more
20172 citations
Semantic Scholar
ASN002 demonstrates efficacy and improves inflammation in AD
R. Bissonnette, C. Maari, S. Forman, N. Bhatia +14 more
2019British Journal of Dermatology1 citations Open access
Semantic Scholar
Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors
D. Rasco, N. Lakhani, R. Sullivan, M. Mita +8 more
2018Clinical Trials1 citations
Semantic Scholar
Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models
Sanjeeva P. Reddy, D. Sivanandhan, Purushottam M. Dewang, N. Rao +2 more
20181 citations
Semantic Scholar
Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models
S. Thompson, R. Smith, N. Rao, M. Wick +1 more
20171 citations
Semantic Scholar
Clinical activity, safety and tolerability of ASN002, a dual SYK/JAK inhibitor, in patients non-Hodgkin lymphoma (NHL) and solid tumors.
D. Rasco, T. O'Rourke, Andy I. Chen, Michael Wang +5 more
20171 citations
Semantic Scholar
ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.
N. Rao, A. Tolcher, K. Papadopoulos, D. Rasco +4 more
20161 citations
Semantic Scholar
Abstract C134: EN3356, a novel CYP17A inhibitor for the treatment of castration resistant prostate cancer.
N. Laping, D. Sivanandhan, R. R. Kethiri, Purushottam M. Dewang +8 more
20131 citations
Semantic Scholar
ASN002 证明有疗效并可改善AD 炎症
R. Bissonnette, C. Maari, S. Forman, N. Bhatia +14 more
2019British Journal of Dermatology0 citations Open access
Semantic Scholar
Abstract 5783: Strong antitumor activity of ASN007, an oral ERK1/2 inhibitor, in PDX tumor models with MAP kinase pathway alterations including KRAS mutations
Sanjeeva P. Reddy, N. Rao, R. Smith, S. Thompson +1 more
2018Experimental and Molecular Therapeutics0 citations
Semantic Scholar
Abstract B147: A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors
D. Rasco, N. Lakhani, R. Sullivan, M. Mita +7 more
20180 citations
Semantic Scholar
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.
J. Garcia, R. Dreicer, A. Pantuck, N. Haas +4 more
20170 citations
Semantic Scholar
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).
J. Garcia, R. Dreicer, A. Pantuck, N. Haas +8 more
20170 citations
Semantic Scholar
371PDA Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
D. Rasco, R. Sullivan, N. Lakhani, Sanjeeva P. Reddy +4 more
20170 citations Open access
Semantic Scholar
Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,
A. Perl, Grace R. Jeschke, Takashi Sato, Akinaga Shiro +4 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Sanjeeva P. Reddy×15
Invite
Sanjeeva P. Reddy — researcher profile on SciRah
L. Denis×13
Invite
L. Denis — researcher profile on SciRah
D. Rasco×9
Invite
D. Rasco — researcher profile on SciRah
A. Tolcher×9
Invite
A. Tolcher — researcher profile on SciRah

×8

Invite

R. Smith — researcher profile on SciRah

Invite

D. Zammit — researcher profile on SciRah

Akinaga Shiro×5

Invite

Akinaga Shiro — researcher profile on SciRah

Invite

M. Levis — researcher profile on SciRah

R. Bissonnette×5

Invite

R. Bissonnette — researcher profile on SciRah

Invite

H. Usansky — researcher profile on SciRah

Invite

T. Song — researcher profile on SciRah

Invite

A. Pavel — researcher profile on SciRah